Loading...

PolarityTE

DB:NJTC
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NJTC
DB
$194M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • PolarityTE has significant price volatility in the past 3 months.
NJTC Share Price and Events
7 Day Returns
-13.7%
DB:NJTC
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-49.1%
DB:NJTC
-9.2%
DE Biotechs
-6.7%
DE Market
NJTC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PolarityTE (NJTC) -13.7% -38.3% -49.6% -49.1% 82.2% 361.9%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • NJTC underperformed the Biotechs industry which returned -9.2% over the past year.
  • NJTC underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
NJTC
Industry
5yr Volatility vs Market
Related Companies

NJTC Value

 Is PolarityTE undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of PolarityTE to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for PolarityTE.

DB:NJTC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NJTC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0.52%))
1.31
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.31 * 5.96%)
8.03%

Discounted Cash Flow Calculation for DB:NJTC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for PolarityTE is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:NJTC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.03%)
2019 -96.50 Analyst x2 -89.32
2020 -84.00 Analyst x2 -71.97
2021 -61.00 Analyst x2 -48.38
2022 -7.00 Analyst x2 -5.14
2023 59.00 Analyst x2 40.09
2024 96.88 Est @ 64.21% 60.94
2025 140.49 Est @ 45.01% 81.80
2026 184.85 Est @ 31.58% 99.63
2027 225.84 Est @ 22.17% 112.67
2028 261.04 Est @ 15.59% 120.55
Present value of next 10 years cash flows $300.86
DB:NJTC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $261.04 × (1 + 0.23%) ÷ (8.03% – 0.23%)
$3,352.31
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,352.31 ÷ (1 + 8.03%)10
$1,548.06
DB:NJTC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $300.86 + $1,548.06
$1,848.93
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,848.93 / 23.77
$77.79
DB:NJTC Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NJTC represents 0.87408x of NasdaqCM:PTE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87408x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 77.79 x 0.87408
€67.99
Value per share (EUR) From above. €67.99
Current discount Discount to share price of €7.15
= -1 x (€7.15 - €67.99) / €67.99
89.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price PolarityTE is available for.
Intrinsic value
>50%
Share price is €7.15 vs Future cash flow value of €67.99
Current Discount Checks
For PolarityTE to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • PolarityTE's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • PolarityTE's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PolarityTE's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PolarityTE's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NJTC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.18
NasdaqCM:PTE Share Price ** NasdaqCM (2019-04-18) in USD $8.18
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PolarityTE.

DB:NJTC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:PTE Share Price ÷ EPS (both in USD)

= 8.18 ÷ -5.18

-1.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PolarityTE is loss making, we can't compare its value to the Europe Biotechs industry average.
  • PolarityTE is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does PolarityTE's expected growth come at a high price?
Raw Data
DB:NJTC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
29%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PolarityTE, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PolarityTE's assets?
Raw Data
DB:NJTC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.46
NasdaqCM:PTE Share Price * NasdaqCM (2019-04-18) in USD $8.18
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:NJTC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:PTE Share Price ÷ Book Value per Share (both in USD)

= 8.18 ÷ 3.46

2.36x

* Primary Listing of PolarityTE.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PolarityTE is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess PolarityTE's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. PolarityTE has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NJTC Future Performance

 How is PolarityTE expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PolarityTE expected to grow at an attractive rate?
  • Unable to compare PolarityTE's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare PolarityTE's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • PolarityTE's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NJTC Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NJTC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 29%
DB:NJTC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 55.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NJTC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NJTC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 257 60 -1 3
2022-12-31 183 -29 -54 3
2021-12-31 115 -94 -97 3
2020-12-31 46 -100 -109 5
2019-12-31 18 -111 -109 4
DB:NJTC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -48 -111
2018-10-31 2 -29 -74
2018-07-31 0 -20 -62
2018-04-30 0 -15 -50
2018-01-31 0 -12 -141
2017-10-31 -8 -131
2017-07-31 -5 -121
2017-04-30 -1 -3 -118
2017-01-31 -1 -2 -8
2016-10-31 -2 -10
2016-07-31 0 -2 -10
2016-04-30 3 -4 -9
2016-01-31 4 -4 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PolarityTE is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • PolarityTE's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NJTC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from PolarityTE Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NJTC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.06 0.60 -0.36 3.00
2022-12-31 -1.43 -0.70 -2.35 3.00
2021-12-31 -2.81 -2.15 -3.87 3.00
2020-12-31 -3.88 -3.39 -4.46 4.00
2019-12-31 -4.51 -3.45 -6.01 5.00
DB:NJTC Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.18
2018-10-31 -4.86
2018-07-31 -5.39
2018-04-30 -6.38
2018-01-31 -24.56
2017-10-31 -26.60
2017-07-31 -30.13
2017-04-30 -36.52
2017-01-31 -3.35
2016-10-31 -4.69
2016-07-31 -5.57
2016-04-30 -5.66
2016-01-31 -8.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PolarityTE will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess PolarityTE's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PolarityTE has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NJTC Past Performance

  How has PolarityTE performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PolarityTE's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PolarityTE does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare PolarityTE's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare PolarityTE's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
PolarityTE's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PolarityTE Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NJTC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.04 -110.51 91.84 20.75
2018-10-31 1.56 -74.16 50.56 19.38
2018-07-31 0.43 -61.77 38.98 17.34
2018-04-30 0.02 -49.80 25.58 18.49
2018-01-31 0.01 -141.01 24.94 117.95
2017-10-31 -130.97 18.81 111.80
2017-07-31 -121.32 13.33 108.12
2017-04-30 -1.00 -117.69 12.53 104.64
2017-01-31 -0.59 -8.42 8.18 -0.04
2016-10-31 -9.84 4.10
2016-07-31 0.43 -10.18 4.71 0.08
2016-04-30 2.52 -8.82 4.95 0.17
2016-01-31 3.81 -11.16 5.08 0.18
2015-10-31 6.69 -6.06 6.12 0.17
2015-07-31 12.55 -10.64 8.55 0.39
2015-04-30 14.37 -13.09 10.22 0.73
2015-01-31 15.91 -13.24 11.65 1.12
2014-10-31 34.37 -16.20 15.63 2.34
2014-07-31 38.16 -15.41 16.00 2.70
2014-04-30 39.25 -16.33 16.44 3.67
2014-01-31 45.73 -15.01 17.21 4.71
2013-10-31 47.27 -12.64 17.03 5.54
2013-07-31 63.75 -10.79 18.80 6.78
2013-04-30 68.90 -10.23 20.47 7.34
2013-01-31 89.58 -5.25 24.16 7.56
2012-10-31 132.29 4.61 30.18 7.78
2012-07-31 130.86 3.45 29.62 7.73
2012-04-30 141.26 8.42 29.34 7.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if PolarityTE has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if PolarityTE has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if PolarityTE improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess PolarityTE's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PolarityTE has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NJTC Health

 How is PolarityTE's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PolarityTE's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PolarityTE is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PolarityTE's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of PolarityTE's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 63.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PolarityTE Company Filings, last reported 3 months ago.

DB:NJTC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 72.03 1.01 61.84
2018-10-31 81.66 1.26 70.96
2018-07-31 92.43 1.24 84.83
2018-04-30 41.65 0.00 37.84
2018-01-31 1.80 0.00 9.99
2017-10-31 4.71 0.00 17.67
2017-07-31 4.16 0.00 3.06
2017-04-30 5.64 0.00 4.81
2017-01-31 6.51 0.00 6.90
2016-10-31 5.40 0.00 6.52
2016-07-31 5.50 0.00 6.74
2016-04-30 6.14 0.00 7.35
2016-01-31 5.69 0.00 6.65
2015-10-31 15.66 0.00 17.05
2015-07-31 6.77 0.00 8.58
2015-04-30 5.59 0.00 9.08
2015-01-31 4.93 0.00 10.48
2014-10-31 5.55 0.00 7.20
2014-07-31 10.26 0.00 10.94
2014-04-30 12.70 0.00 10.95
2014-01-31 15.97 0.00 12.35
2013-10-31 20.05 1.76 13.39
2013-07-31 22.24 1.16 18.83
2013-04-30 25.54 0.00 25.54
2013-01-31 27.43 0.00 26.76
2012-10-31 29.34 0.00 18.04
2012-07-31 31.78 0.65 27.29
2012-04-30 34.44 0.00 31.73
  • PolarityTE's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (3.3% vs 1.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • PolarityTE has sufficient cash runway for 1.2 years based on current free cash flow.
  • PolarityTE has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 96.7% each year.
X
Financial health checks
We assess PolarityTE's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PolarityTE has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NJTC Dividends

 What is PolarityTE's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from PolarityTE dividends.
If you bought €2,000 of PolarityTE shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate PolarityTE's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate PolarityTE's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NJTC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NJTC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as PolarityTE has not reported any payouts.
  • Unable to verify if PolarityTE's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of PolarityTE's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as PolarityTE has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess PolarityTE's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PolarityTE afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PolarityTE has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NJTC Management

 What is the CEO of PolarityTE's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Denver Lough
AGE 37
TENURE AS CEO 2.3 years
CEO Bio

Dr. Denver M. Lough, M.D., Ph.D., has been the Chairman, Chief Executive Officer, Chief R&D Officer and President of PolarityTE, Inc. since December 1, 2016 and served as its Chief Scientific Officer. Dr. Lough founded PolarityTE, LLC, PolarityTE, Inc. and Lough & Associates LLC which are engaged in the business of developing intellectual property related to regenerative medicine and related fields. Dr. Lough has been the Chairman, Chief Executive Officer and Chief Scientific Officer of Majesco Entertainment Company since December 1, 2016. Dr. Lough served as Department of Surgery Faculty and Translational Research Director at Laboratory for Regenerative Medicine and Applied Sciences, Institute for Plastic Surgery Southern Illinois University School of Medicine since August 2009. He served as a Director of Biomedical Applications for Laboratory for Craniofacial Regenerative Medicine Johns Hopkins Hospital Department of Plastic and Reconstructive Surgery since June 2013. In addition, Dr. Lough was a lead research associate in the Vascularized Composite Allotransplantation Laboratory at the Johns Hopkins Hospital Department of Plastic and Reconstructive Surgery and has been a research consultant to the Johns Hopkins Hendrix Burn Research Center. Dr. Lough was assembled as a member among other burn experts as a Taiwanese presidential disaster response team following the largest civilian burn disaster in 2015. Since 2012, he has been a Plastic & Reconstructive Surgery House Staff Officer at Johns Hopkins University School of Medicine, Department of Plastic & Reconstructive Surgery. Dr. Lough has received numerous accolades and awards by national societies related to basic and translational science applications in tissue engineering, regenerative medicine and immunology as well as within solid organ and reconstructive transplantation. He has experience in clinical medicine and surgery as well as the development and innovation of technologies related to regenerative medicine and related patents and intellectual property which Company has reviewed for potential development. Dr. Lough holds an M.D. and PhD in Biochemistry, Molecular and Cell Biology from Georgetown University which he earned in 2012.

CEO Compensation
  • Insufficient data for Denver to compare compensation growth.
  • Insufficient data for Denver to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the PolarityTE management team in years:

0.8
Average Tenure
48
Average Age
  • The average tenure for the PolarityTE management team is less than 2 years, this suggests a new team.
Management Team

Denver Lough

TITLE
Chairman of the Board
AGE
37
TENURE
2.3 yrs

Paul Mann

TITLE
Chief Financial Officer
TENURE
0.8 yrs

Richard Hague

TITLE
Chief Operating Officer
AGE
58

David Blum

TITLE
Chief Design & Technology Officer

Nikolai Sopko

TITLE
Chief Scientific Officer and VP of R&D
TENURE
0.8 yrs

Rich Haerle

TITLE
Vice President of Investor Relations & Strategy
TENURE
0.9 yrs

Holly Kramen

TITLE
Chief Compliance Officer & Privacy Officer
TENURE
1.4 yrs

Mark Lehman

TITLE
Chief Legal Officer

David Seaburg

TITLE
President of Corporate Development & Director
AGE
48
TENURE
0.1 yrs

Alain Adam

TITLE
Vice President of Sales
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the PolarityTE board of directors in years:

2.3
Average Tenure
54
Average Age
  • The average tenure for the PolarityTE board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Seaburg

TITLE
President of Corporate Development & Director
AGE
48
TENURE
0.7 yrs

Stephen Milner

TITLE
Chief Clinical Officer & Member of Clinical Advisory Board
AGE
69
TENURE
2.3 yrs

Maurice Nahabedian

TITLE
Chief Surgical Officer & Member of Clinical Advisory Board

Jeff Dyer

TITLE
Independent Director
AGE
59
TENURE
2.1 yrs

Denver Lough

TITLE
Chairman of the Board
AGE
37
TENURE
2.3 yrs

Michael Grant

TITLE
Member of Clinical Advisory Board
TENURE
2.3 yrs

Anand Kumar

TITLE
Member of Clinical Advisory Board
TENURE
2.3 yrs

Steve Gorlin

TITLE
Independent Director
AGE
80
TENURE
2.2 yrs

Jon Mogford

TITLE
Independent Director
AGE
49
TENURE
2.2 yrs

Michael Callahan

TITLE
Member of Clinical Advisory board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Oct 18 Sell John Stetson Individual 27. Sep 18 04. Oct 18 -297,500 €16.73 €-4,836,204
19. Sep 18 Buy Edward Swanson Individual 18. Sep 18 18. Sep 18 500 €14.77 €7,387
19. Sep 18 Buy Paul Mann Individual 18. Sep 18 18. Sep 18 20,000 €14.75 €294,973
18. Sep 18 Buy Ramses Erdtmann Individual 14. Sep 18 14. Sep 18 6,680 €14.94 €99,784
26. Jul 18 Buy Peter Cohen Individual 25. Jul 18 25. Jul 18 6,000 €20.83 €119,227
X
Management checks
We assess PolarityTE's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PolarityTE has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NJTC News

Simply Wall St News

NJTC Company Info

Description

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Details
Name: PolarityTE, Inc.
NJTC
Exchange: DB
Founded:
$172,964,945
23,768,951
Website: http://www.polarityte.com
Address: PolarityTE, Inc.
123 North Wright Brothers Drive,
Salt Lake City,
Utah, 84116,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM PTE Common Stock Nasdaq Capital Market US USD 08. Dec 2003
DB NJTC Common Stock Deutsche Boerse AG DE EUR 08. Dec 2003
Number of employees
Current staff
Staff numbers
156
PolarityTE employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 20:55
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.